Amicus Therapeutics, Inc. (FOLD)
Market Cap | 3.10B |
Revenue (ttm) | 329.23M |
Net Income (ttm) | -236.57M |
Shares Out | 282.72M |
EPS (ttm) | -0.82 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,025,482 |
Open | 11.22 |
Previous Close | 11.23 |
Day's Range | 10.85 - 11.29 |
52-Week Range | 5.91 - 13.84 |
Beta | 0.82 |
Analysts | Buy |
Price Target | 16.04 (+46.48%) |
Earnings Date | May 8, 2023 |
About FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate t... [Read more]
Financial Performance
In 2022, FOLD's revenue was $329.23 million, an increase of 7.76% compared to the previous year's $305.51 million. Losses were -$236.57 million, -5.55% less than in 2021.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is $16.04, which is an increase of 46.48% from the latest price.
News

Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe
Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).

WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
WUXI, China , March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic ...

Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease

Amicus (FOLD) Q4 Earnings Miss, Galafold Sales Beat Estimates
Amicus (FOLD) posts a wider-than-expected fourth-quarter loss but strong sales of its solely marketed drug Galafold drive the top line.

Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -46.15% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
2022 Revenue Growth of 16% at CER to $329M

Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference i...

Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk, Forced Vital Capacity for ERT-Naïve and ERT-Experienced Participants Out to Two Years

Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
PHILADELPHIA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at 8:...

Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
PHILADELPHIA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 11 posters across its development programs will be included at the 1...

Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
PHILADELPHIA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference...

Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
Significant Growth in Demand with More Than 2,000 People Living with Fabry Disease on Galafold by End of 2022

Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P. Mo...

Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data

Why Is Amicus Therapeutics (FOLD) Up 13.7% Since Last Earnings Report?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
PHILADELPHIA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New Y...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD
NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (NASDAQ: FOLD). Such investors are advise...

Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
PHILADELPHIA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare ...

Amicus Therapeutics (FOLD) Reports Q3 Loss, Misses Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 36.84% and 3.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
Year-to-Date 2022 Reported Revenue Growth of 8% (16% at CER)

U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date

Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
PHILADELPHIA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 7, 2022 at 8:...

Amicus Therapeutics Announces Participation at World Muscle Society 2022
PHILADELPHIA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced four poster presentations highlighting its development program for Pompe disease will be included at...

Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting
PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be included ...